Trilostane dose versus body weight in the treatment of naturally occurring pituitary-dependent hyperadrenocorticism in dogs.
E C Feldman, P H Kass
文献索引:J. Vet. Intern. Med. 26(4) , 1078-80, (2012)
全文:HTML全文
摘要
Trilostane is commonly used in the treatment of dogs with naturally occurring pituitary-dependent hyperadrenocorticism (PDH). Dose recommendations have varied from the manufacturer and the literature.As body weight increases, dose/kg or dosage/day of trilostane required to control the clinical signs of PDH decreases.70 dogs with naturally occurring hyperadrenocorticism.Retrospective study. Each dog must have been treated for at least 6 months and should have shown a "good response" to trilostane, as determined by owners. Statistical comparisons of dose and dosage were made after the dogs were separated into groups weighing <15 or >15 kg; groups weighing ≤10, 10.1-20, 20.1-30, and ≥30 kg; and then groups based on body surface area versus dose/kg and total amount of trilostane required to control the condition.There was no significant difference in trilostane dose in mg/kg of body weight or in the total amount of trilostane required daily to control clinical signs, except when the dose for dogs weighing >30 kg was compared with that for the other groups. However, despite lack of statistical significance when comparing groups, there was a significant trend using polynomial regression analysis, suggesting that as body weight increases, the amount of trilostane (mg/kg/dose as well as mg/kg/daily dosage) required to control clinical signs decreases.Dogs weighing >30 kg, and possibly those weighing >15 kg, might require smaller amounts of trilostane per dose or per day than those weighing less, to control PDH-associated clinical signs.Copyright © 2012 by the American College of Veterinary Internal Medicine.
相关化合物
相关文献:
2015-04-01
[Steroids 96 , 153-63, (2015)]
2016-01-01
[Endocr. J. 63 , 77-85, (2016)]
2010-11-01
[Toxicol. Sci. 118(1) , 61-70, (2010)]
2011-09-01
[Environ. Toxicol. Chem. 30(9) , 2094-102, (2011)]
2010-09-01
[Hypertens. Res. 33(9) , 872-5, (2010)]